Sales of Novo Nordisk's Victoza drop in US

Diabetes drug Victoza has had lower sales this year than during the same period last year.

Photo: Novo Nordisk Pharmatech/PR

Novo Nordisk's best selling drug, diabetes medicine Victoza, has lost momentum in the US over the past few weeks.

Sales have fallen by 2 percent over the past month, data provided by US analysis house Symphony Health shows.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs